MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.55
-0.31
-1.40%
Opening 14:07 06/22 EDT
OPEN
21.76
PREV CLOSE
21.85
HIGH
22.00
LOW
21.20
VOLUME
65.25K
TURNOVER
--
52 WEEK HIGH
31.27
52 WEEK LOW
10.18
MARKET CAP
826.24M
P/E (TTM)
-8.2039
1D
5D
1M
3M
1Y
5Y
Merus upgraded on ASCO update, Cantor favors Harpoon after selloff; and more in today’s analyst action
Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral.
Seekingalpha · 06/07 12:49
BNGO, CLNE, MVIS and CLOV among notable premarket gainers
Ra Medical Systems (RMED) +56%.Liminal BioSciences (LMNL) +42%.NextDecade Corporation (NEXT) +30%.U.S. Concrete (USCR) +28% as Vulcan Materials buys the Company in $1.3B deal.QTS Realty Trust (QTS) +20% on being acquired by Blackstone
Seekingalpha · 06/07 12:23
10 Biggest Price Target Changes For Monday
Wells Fargo boosted the price target for American Express Company (NYSE: AXP) from $165 to $185. American Express shares rose 0.3% to close at $165.00 on Friday.
Benzinga · 06/07 11:48
Citigroup Upgrades Merus to Buy, Raises Price Target to $31
Citigroup analyst Yigal Nochomovitz upgrades Merus (NASDAQ:MRUS) from Neutral to Buy and raises the price target from $24 to $31.
Benzinga · 06/07 10:50
Citigroup Lifts Merus NV to Buy From Neutral, Price Target to $31 From $24
MT Newswires · 06/07 07:03
Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers
Benzinga · 06/04 19:37
Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Merus ([[MRUS]] +1.6%) announces positive interim efficacy data from the phase 1/2 eNRGy trial of bispecific antibody zenocutuzumab ((Zeno)) in patients with NRG1+ cancers.61 patients with NRG1+ cancer have been
Seekingalpha · 06/04 16:10
Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting
Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and
Benzinga · 06/04 16:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRUS. Analyze the recent business situations of Merus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRUS stock price target is 30.50 with a high estimate of 36.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 29.34M
% Owned: 76.51%
Shares Outstanding: 38.35M
TypeInstitutionsShares
Increased
22
3.87M
New
20
2.96M
Decreased
8
1.77M
Sold Out
4
380.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
-0.52%
Key Executives
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
John de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Lex Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Other
L. Andres Sirulnik
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
No Data
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.